Compare AEYE & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEYE | ACRV |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | 116 | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.0M | 82.2M |
| IPO Year | 2011 | 2022 |
| Metric | AEYE | ACRV |
|---|---|---|
| Price | $7.24 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $14.63 | $11.67 |
| AVG Volume (30 Days) | 122.9K | ★ 506.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.56 | 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,311,000.00 | N/A |
| Revenue This Year | $11.12 | N/A |
| Revenue Next Year | $11.45 | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.52 | N/A |
| 52 Week Low | $5.31 | $1.05 |
| 52 Week High | $16.39 | $3.56 |
| Indicator | AEYE | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 46.66 |
| Support Level | $6.50 | $1.73 |
| Resistance Level | $7.42 | $1.86 |
| Average True Range (ATR) | 0.52 | 0.12 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 56.36 | 25.38 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.